产品名称
硫利达嗪, European Pharmacopoeia (EP) Reference Standard
SMILES string
S1c2c(cc(cc2)SC)N(c4c1cccc4)CCC3N(CCCC3)C
InChI
1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
InChI key
KLBQZWRITKRQQV-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
thioridazine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
Application
Thioridazine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
It is anticipated that as is usually the case, financial motivation will move TZ from its current status “potential anti-MDR/XDR agent,” to one that will cure MDR and XDR TB. Foreword.
Leonard Amaral
Recent patents on anti-infective drug discovery, 6(2), 76-76 (2011-07-30)
Shen-Chieh Chang et al.
Therapeutic drug monitoring, 34(3), 345-348 (2012-05-10)
In this study, the authors studied the effect of thioridazine (TDZ) on the pharmacokinetic profile of quetiapine (QTP) in Taiwanese patients with schizophrenia. Sixteen subjects with schizophrenia were recruited for this study. The authors pretreated 8 patients with TDZ 50
Diana Machado et al.
PloS one, 7(4), e34538-e34538 (2012-04-12)
Multidrug resistant (MDR) tuberculosis is caused by Mycobacterium tuberculosis resistant to isoniazid and rifampicin, the two most effective drugs used in tuberculosis therapy. Here, we investigated the mechanism by which resistance towards isoniazid develops and how overexpression of efflux pumps
Maija Purhonen et al.
Pharmacoepidemiology and drug safety, 21(11), 1227-1231 (2012-09-04)
Thioridazine is a first-generation antipsychotic drug that was withdrawn from the market worldwide in 2005. The outcome of clinically stable schizophrenia patients who used thioridazine before market withdrawal was evaluated. Nationwide registers in Finland were utilized to study thioridazine use
Eduardo Abbate et al.
The Journal of antimicrobial chemotherapy, 67(2), 473-477 (2011-12-03)
Current drug choices to treat extensively drug-resistant (XDR) tuberculosis (TB) are scarce; therefore, information on the safety, tolerability and efficacy of alternative regimens is of utmost importance. The aim of this study was to describe the management, drug adverse effects
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持